Why the cannabis stock exchange has cost billions

2019 was the year of big deals on the cannabis market. Due to the hype about cannabis and its ingredients, many new companies were founded. However, many smaller companies could not have withstood the competition on their own which made mergers important in order to establish themselves on the market. Regulations and scandals play a role in market fluctuations that investors hope will balance out.

A real cannabis stock exchange boom started about two years ago. Thanks to the legalization of cannabis in Canada and some states in the U.S., Canopy Growth, Aurora Cannabis, Tilray, Cronos, Hexo became the darlings of investors in 2018.

However, during the course of the following year, the negative headlines in the cannabis stock exchange increased and some companies fell short of expectations with their figures, sometimes significantly.

Let’s discuss why things went downhill for many cannabis companies in the last months, what gives investors hope now and how the cannabis business could continue in 2020.

Curating quality information on only the most promising cannabis companies and the most influential investors, Hemp.im allows you to save time as you stay on top of the latest trends in this dynamic industry of cannabis.

Many mergers create a positive atmosphere for the cannabis stock exchange

Even at the beginning of the year, the development of the cannabis stock exchange for 2019 seemed to know only one direction. Stocks were going upwards, and most analysts agreed.

Cannabis stock exchange expert Jim Cramer called the Canopy Growth stock the best of the market. In just one month, the stock has risen more than 80% and analysts thought it could do even more.

Cramer and Vivien Azer, who is considered the top analyst in the industry, was positive for the entire cannabis stock exchange in 2019.

2019 was the year of big deals on the cannabis market. Due to the hype about the cannabis plant and its ingredients, many new companies were founded. However, many smaller companies could not have withstood the competition on their own, which made mergers important in order to establish themselves on the market.

At the beginning of the year, the big players had already started to buy up smaller companies and this trend continued. In the spring of 2019, for example, Cresco Labs bought up its competitor Origin House for more than a billion dollars.

Deals were not only concluded at this level. Some large Canadian cannabis companies did business with big companies from other sectors, such as Canopy Growth with the beverage manufacturer Constellation Brands or Cronos with the Marlboro manufacturer Altria.

The cannabis stock exchange saw a summer low due to negative market news

Towards the middle of the year, the less pleasant news increased. Some cannabis companies were unable to meet cannabis stock exchange expectations with the publication of their quarterly results.

On top of that, there were other problems and scandals that affected the whole industry. A negative surprise was the dismissal of Bruce Linton at Canopy Growth. He was unable to maintain his position under pressure from Constellation Brands, which was visibly dissatisfied with Canopy’s increasing losses.

Meanwhile, competitor Curaleaf filed a warning from the Food and Drug Administration (FDA). The reason was probably the aggressive approach of the company, which entered into a partnership with the drugstore chain CVS.

The FDA accused Curaleaf of claiming that the products marketed by CVS could be used to treat serious diseases.

CannTrust caused a stir with a scandal involving unauthorized cannabis cultivation areas. As a result, the Canadian Ministry of Health confiscated several tons of cannabis. Subsequently, it became known that parts of this illegal production had already been exported abroad and that the management knew about the plan.

The fact that progress on cannabis legalization in the U.S. was still a long time coming also caused a subdued mood.

Millions lost on the cannabis stock exchange

The cannabis companies invested more and more in their growth, even across borders, but they could not convert the investments into profits and had to take heavy losses.

Neither Hexo nor Aurora Cannabis or Canopy Growth could meet the expectations of the analysts. So, in late summer, even experts became more skeptical about the entire Canadian cannabis stock exchange. After Hexo shocked with a sales warning, analysts punished not only Hexo but Canopy Growth as well.

They advised investors to move their investments from Canadian corporations to the U.S. so the so-called MSOs (multi-state operators) would not be so badly affected by the headlines.

Following the sales warning and negative analyst comments, Hexo announced that the group had cut around 200 jobs and closed individual plants. Not only Canadian companies were affected though, MedMen, a U.S. corporation, also had to lay off about a fifth of its workforce.

The prices of cannabis companies also recorded losses accordingly. For Hexo shares, the NYSE has seen a 56.84% decline to $2.24 since the IPO in January. Canopy Growth shares lost 23.04% to $20.68, after having been around six dollars higher at the start of the year.

Additionally, Aurora Cannabis shares fell by a full 46.98% to $2.63 while stocks of CannTrust are still trading for $0.84, a drop of 82.49% at the beginning of the year. Aphria has lost 3.34% to $5.50 and Tilray shares cost 73.63% less on the Nasdaq at $18.60. Furthermore, Cronos shares show a year-to-date discount of 29.93% to $7.28 (as of December 2019.)

Bad figures come from diverse reasons

Where do the bad figures on the cannabis stock exchange come from? The managers of some of the biggest companies themselves cited reasons such as the lack of shops, a lack of supply of high-quality cannabis, the strong illegal market trade and also uncertainties in connection with expansion plans towards Europe.

Of course, the unclear regulations in the U.S. concerning the sale of CBD products, would have led to many shops not selling the products.

Financial analyst Clemens Schmale explained that investors priced in the expectation of a high turnover much too early.

“The sector has been valued at what might be 10 or 20 years from now,” said Schmale.

Schmale already warned that cannabis stocks are “irrationally overvalued” in 2018 and are “most likely in the final stages of the euphoria phase.”

What will happen in 2020?

Cannabis is still illegal at the federal level in the U.S., but the individual states can set up laws deviating from this law. As such, there is a patchwork of regulations in the U.S.

In some states, cannabis has been completely legalized and in others, cannabis is only allowed for medical purposes. Furthermore, a number of states have decriminalized medical cannabis while a number of others have decriminalized both recreational and medical cannabis.

However, there are still some states where cannabis remains illegal. In others, possession of small quantities is only punished as a minor offence but there are still some states where marijuana possession can lead to imprisonment.

Further developments in the U.S. legalization issue will be decisive for the future of the cannabis stock exchange. If Washington, Oregon, Nevada, California, Colorado, Alaska, Michigan, Maine, Vermont, and Massachusetts are followed by other states that legalize the cultivation, sale, and consumption of cannabis, this could support the industry again.

Hurdles to the cannabis stock exchange continue abroad

However, developments in Europe should also remain interesting for cannabis companies. In Europe, they are also still confronted with regulatory hurdles.

But as long as the markets for cannabis companies remain so restricted and sales cannot develop in line with the exponential growth of the companies, cannabis companies should probably first try to contain their costs and become profitable in the long run.

Investors should be aware that it may be some time before there is a world market for cannabis and better improvements on the cannabis stock exchange.

__

(Featured image by kaboompics via Pixabay)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Hemp.im, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in finanzen, a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Hemp.im assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Hemp.im is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.